Somewhere it was noted that the US FDA had stipulated that the Xanamen trial be at the 10mg dose level. ACW sought to have a higher dose level, but had to go with the lower dose to get the trial approved in the US. My understanding was that as soon as possible they had desired to put in place trials at a higher dose level, which is currently underway. It would appear the DSMB reviews have been handy in enabling this higher dose trial to go ahead.
It is good to raise these questions as there would be numerous potential investors who haven't seen the whole story. Cheers DYOR
Ann: DSMB again reaffirms XanADu trial to continue without change, page-50
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.98M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.5¢ | 2.3¢ | $146.4K | 5.980M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1293461 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 336163 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |